Merck KGaA continues focus on strengthening pipeline with external innovation, says CFO on drug trials
Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.
Hosted on MSN8h
Merck KGaA Expects Sales at Lower End of Outlook Range After Third-Quarter Miss
Germany’s Merck KGaA expects annual sales to be at the lower half of its outlook range after third-quarter sales missed ...
The Pharma Letter57m
Merck KGaA shares slip on cautious outlook
Germany’s Merck KGaA (MRK: DE) was trading 5% lower as Thursday’s trading day neared its end, after the company announced ...
ENDPOINTS NEWS2h
Mer­ck KGaA’s life sci­ence unit is still feel­ing the Covid de­mand de­cline
Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...
Merck KGaA stock falls on weak Q3, soft outlook
Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...
FierceBiotech2d
Merck KGaA's phase 3 rare tumor trial hits goal, teeing up rivalry with Daiichi and Ono
Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...
bnnbloomberg8h
Merck KGaA Beats Estimates on Boost From Life Science Unit
(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic ...
pharmaphorum2d
Merck drug for rare tumour hits phase 3 target
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...
Merck KGaA: A Continued Long-Term Upside Despite Some Lag
Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...
Merck Foundation Marking "World Diabetes Day" by Providing out of 2080 Scholarships, 830 Scholarships for Diabetes and Hypertension in 52 Countries
BusinessWire India Accra [Ghana] Mumbai Maharashtra [India] November 14 Merck Foundation the philanthropic arm of Merck KGaA ...
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...